RecruitingNCT06963021
NBI-1065845 added to care for major depression
About this title
Read the official source — NCT06963021This study evaluates the safety and effectiveness of NBI-1065845 for people with depression.
Medication studyAges 18+Multiple countries
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of NBI-1065845 for people with depression.
Who could participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
What will I do during this study?
You are randomly assigned to receive NBI-1065845 or a matching placebo (an inactive comparison treatment) by mouth once a day, alongside your current treatment. The main symptom measure is assessed through day 56. The registry does not specify the visit schedule in the information reviewed here.
- Listed locations
- Chino and 34 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 30, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 200
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, United Kingdom, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT06963021
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Chino, United States · Los Angeles, United States · Stanford, United States
29 more locations
- Aurora, United States
- Cromwell, United States
- Farmington, United States
- Maitland, United States
- Miami, United States
- Tampa, United States
- Gaithersburg, United States
- Cedarhurst, United States
- New York, United States
- Charlotte, United States
- Philadelphia, United States
- Alken, Belgium
- Bruges, Belgium
- Mechelen, Belgium
- Toronto, Canada
- Verdun, Canada
- Kuopio, Finland
- Oulu, Finland
- Tampere, Finland
- Budapest, Hungary
- Gyöngyös, Hungary
- Kalocsa, Hungary
- Jelgava, Latvia
- Liepāja, Latvia
- Sigulda, Latvia
- London, United Kingdom
- Salford, United Kingdom
- Sheffield, United Kingdom
- Southampton, United Kingdom
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of NBI-1065845 for people with depression.
Who is behind this study?
The study sponsor is Neurocrine Biosciences, a biotech company.
Does this study involve medication?
Yes. The study involves medication, including NBI-1065845 and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
